HARBIN, China, March 12 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. (''China Sky One Medical'' or ''the Company'') (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China (''PRC''), today announced that it obtained approval from the State Food and Drug Administration (SFDA) in China for the production of Policresulen vaginal suppositories.
Policresulen vaginal suppositories are indicated for the treatment of cervical erosion, cervicitis, various vaginal inflammations resulting from bacteria, trichomoniasis or candidiasis, and for pressure ulcers due to vaginal pessary. The active ingredient in Policresulen vaginal suppositories is Policresulen, a topical haemostatic and antiseptic. This new product will be available to consumers around June of 2009.
''We are very pleased to receive SFDA approval in a timely manner, which continues to enable us to benefit from the increasing medical consumption in China tied to new health care reforms and a rising middle class,'' said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. ''We remain confident in our ability to identify drugs that have strong market potential that will enhance our portfolio.''
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company (''Jin Chuang'') the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact: Company Contact: China Sky One Medical, Inc. Mr. Yu-Bo Hao, CFO Tel: +86-451-5399-4069 Email: firstname.lastname@example.org Investor Relations Contact: CCG Investor Relations Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: email@example.com Web: http://www.ccgirasia.com
|SOURCE China Sky One Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved